307 related articles for article (PubMed ID: 16874853)
1. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
2. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
4. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
5. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
He H; Mennone A; Boyer JL; Cai SY
Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
[TBL] [Abstract][Full Text] [Related]
6. Heart and bile acids - Clinical consequences of altered bile acid metabolism.
Vasavan T; Ferraro E; Ibrahim E; Dixon P; Gorelik J; Williamson C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1345-1355. PubMed ID: 29317337
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
9. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
10. Bile salts and cholestasis.
Maillette de Buy Wenniger L; Beuers U
Dig Liver Dis; 2010 Jun; 42(6):409-18. PubMed ID: 20434968
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of cholestasis.
Zollner G; Trauner M
Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
[TBL] [Abstract][Full Text] [Related]
12. The rationale for using ursodeoxycholic acid in chronic liver disease.
Heller FR; Martinet JP; Henrion J; Schapira M; Gallez JF
Acta Gastroenterol Belg; 1990; 53(4):402-8. PubMed ID: 2096588
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
14. Learning from the pregnane X receptor: how to fight one aggressor with two strategies.
Rust C; Beuers U
Liver Int; 2010 Feb; 30(2):161-3. PubMed ID: 20456034
[No Abstract] [Full Text] [Related]
15. Bile acids evoke placental inflammation by activating Gpbar1/NF-κB pathway in intrahepatic cholestasis of pregnancy.
Zhang Y; Pan Y; Lin C; Zheng Y; Sun H; Zhang H; Wang J; Yuan M; Duan T; Du Q; Chen J
J Mol Cell Biol; 2016 Dec; 8(6):530-541. PubMed ID: 27402811
[TBL] [Abstract][Full Text] [Related]
16. Role of apoptosis in the remodeling of cholestatic liver injury following release of the mechanical stress.
Costa AM; Tuchweber B; Lamireau T; Yousef IM; Balabaud C; Rosenbaum J; Desmoulière A
Virchows Arch; 2003 Apr; 442(4):372-80. PubMed ID: 12715172
[TBL] [Abstract][Full Text] [Related]
17. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
18. Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.
Gehrke N; Nagel M; Straub BK; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM
Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G319-G333. PubMed ID: 29191940
[TBL] [Abstract][Full Text] [Related]
19. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.
Beuers U; Spengler U; Zwiebel FM; Pauletzki J; Fischer S; Paumgartner G
Hepatology; 1992 Apr; 15(4):603-8. PubMed ID: 1551637
[TBL] [Abstract][Full Text] [Related]
20. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
